Chatham, NJ – According to filings with the U.S. Securities and Exchange Commission, Evergreen Theragnostics is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Cook played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Evergreen Theragnostics

Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO). Our team’s unmatched expertise and track record in theragnostic radiopharmaceutical commercialization, manufacturing process development, and regulatory affairs management, make us your ideal partner for all of your radiopharmaceutical development, manufacturing, and commercialization needs.

To learn more about Evergreen Theragnostics, visit http://evergreentgn.com/

Contact:
James Cook, Chief Executive Officer
917-319-1920
https://www.linkedin.com/in/james-cook-91a0002/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved